TAGLN was strongly expressed in glioma cells in 41 of 45 (91.1%) of GBMs, 11 of 13 (84.6%) of grade 3 gliomas, but in fewer than 30% of grade 2 gliomas, and was absent in normal brain tissues (Figure 1E,F). Here, TAGLN is linked to central nervous system cancer.